Akèy › Kansè Endomèt › Virginia › Charlottesville
Etid klinik pou Kansè Endomèt nan Charlottesville, VA
13 etid pou Kansè Endomèt ap chèche patisipan nan sit nan ak bò kote Charlottesville (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
Ap rekriteFaz 2
- University of Virginia Cancer Center, Charlottesville
Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer
Ap rekriteFaz 3
- University of Virginia Cancer Center, Charlottesville
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- University of Virginia, Charlottesville
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
Ap rekriteFaz 2
- University of Virginia Cancer Center, Charlottesville
Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER
Ap rekriteFaz 2
- University of Virginia Cancer Center, Charlottesville
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer
Ap rekriteFaz 3
- University of Virginia, Charlottesville
DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer
Ap rekriteFaz 3
- Research Site, Charlottesville
Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors
Ap rekriteFaz 1
- University of Virginia, Charlottesville
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma
Ap rekriteFaz 2
- University of Virginia Health System, Charlottesville
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
Ap rekriteFaz 1/2
- University of Virginia Health System, Charlottesville
FOG-001 in Locally Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1/2
- University of Virginia, Charlottesville
Vaginal Cuff Brachytherapy Fractionation Study
Ap rekriteFaz 3
- University of Virginia, Charlottesville
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Charlottesville
Etid Kansè Endomèt nan lòt vil
- Houston, TX68 etid
- New York City, NY52 etid
- Boston, MA50 etid
- Arlington, VA39 etid
- Nashville, TN38 etid
- Los Angeles, CA34 etid
- St. Louis, MO29 etid
- Philadelphia, PA28 etid
- San Antonio, TX27 etid
- Chicago, IL25 etid
- Columbus, OH25 etid
- Queens, NY25 etid
Lòt etid nan Charlottesville
- Kansè Poumon ki pa ti selil21 etid
- Leksemi mieloïd egi16 etid
- Kansè pwostat15 etid
- Kansè Metastatik13 etid
- Kansè (tout kalite)13 etid
- Kansè poumon13 etid
- Ensifizyans kadyak11 etid
- Kansè ovè10 etid
- Kansè kolorektal10 etid
- Dyabèt tip 19 etid
- Kansè nan tete9 etid
- Kansè pankreyas9 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.